April 2025
RevitalVision Wins Three First Place Awards at ASCRS 2025
Three First Place awards were given to RevitalVision clinical studies at ASCRS 2025, recognizing breakthroughs in Keratoconus and MF-IOL vision improvement.
Congratulations to Dr. Lionel Raj (2 awards) and Dr. Adi Einan-Lifshitz for presenting these outstanding, award-winning studies.
This achievement highlights the growing clinical impact of RevitalVision’s non-invasive, neuroplasticity-based vision therapy.
March 2025
New publihsed study: Long-term efficacy of perceptual learning therapy in amblyopia: A 5-year follow-up study
This new study was just published in the Latin American Journal of Ophthalmology (LAJO) and is the first study to evaluate the long-term effect of RevitalVision on adult patients with amblyopia.
Read article
February 25
RevitalVision makes US debut with digital vision enhancement technology
Eyes On Eyecare magazine has featured RevitalVision’s U.S. debut!
Read more about our journey to innovate vision care.
Read article
December 24
RevitalVision featured on Healio – Improving vision in Keratoconus patients
The article highlights a recent study published in the American Journal of Ophthalmology, showcasing significant vision improvements in keratoconus patients using RevitalVision’s technology.
The study demonstrates how RevitalVision’s targeted vision training improves functional vision with a long-lasting effect in keratoconus patients who are intolerant to contact lenses and do not achieve good vision with spectacles.
November 24
New published study in the American Journal of Ophthalmology- improving vision in Keratoconus
We are proud to share a recently published independent randomized controlled study demonstrating RevitalVision’s efficacy in improving vision in patients with keratoconus. The study was published in the American Journal of Ophthalmology – September 2024
Read article
October 24
Global Action for Eye Health- World Sight Day 2024
In recognition of World Sight Day on October 10, ITN Business has launched a special program that we are proud to have participated in. The “Global Action for Eye Health” initiative focuses on worldwide efforts to enhance eye health, emphasizes the vital need for action, and features inspiring stories of innovation and impact from around the globe. Check out the RevitalVision video created for this important initiative.
Watch the video
August 2024
RevitalVision has been awarded the winner of the VSP Vision Innovation Challenge
VSP Vision, the leader in delivering access to health-focused vision care, and MATTER, the premier healthcare incubator and innovation hub, announce RevitalVision as the winner of the first-ever VSP Vision Innovation Challenge.
Read the announcement
June 2024
ESA-ISA 2024
We are thrilled to announce that Prof. Yair Morad will be presenting RevitalVision at the ESA-ISA 2024 Joint Meeting of the European and International Strabismological Associations, taking place in Toulouse France 13-15 June.
This event brings together the leading minds in pediatric ophthalmology, strabismus, orthoptic, and binocular vision, to share knowledge, exchange ideas, and explore the latest developments in these areas.
Professor Yair Morad will speak about Adult Amblyopia Treatment, sharing the latest clinical trial results withRevitalVision.
June 2024
RevitalVision on Israel21c
ISRAEL21C interviewed Yair Yahav, CEO of RevitalVision about RevitalVision’s home-based vision training program.
The article beautifully illustrates how our simple home-based brain training technology greatly enhances vision and quality of life for our patients
Read the full article
April 2024
Improving Vision in Congenital Nystagmus – Pivotal RCT Results – AAPOS 2024
During the scientific program at AAPOS 2024 in Boston, Dr. Idan Hecht presented the groundbreaking findings from a prospective randomized controlled trial evaluating the efficacy of RevitalVision in improving vision in Congenital Nystagmus patients. the study demonstrated statistically significant improvement in distance and near BCVA, and significant improvement in stereo and binocular functions, offering new hope for nystagmus patients, lacking alternative solutions to improve vision.
Watch presentation
March 2024
RevitalVision Post Crosslinking Surgery Study Won the Best ASCRS Scientific Poster Award
RevitalVision’s study on post crosslinking surgery patients won the best scientific poster award at ASCRS 2024, and was selected for a live presentation.
This prospective, controlled randomized study evaluated the efficacy of RevitalVision’s vision-training software- program in improving best corrected vision in stable keratoconus patients post crosslinking surgery, and showed remarkable clinical outcomes!
The results demonstrated significant improvement in vision, with a mean improvement of 2.5 VA lines, as well as improvements in contrast sensitivity function (CSF) among crosslinked keratoconus patients who received RevitalVision treatment.
We thank Prof. Lional Raj, Prof. David Heber and the rest of Dr.Agarwal’s Eye Hospital Research team for their awarded work!
Read the full abstract
Feb 2024
AECOS (American-European Congress of Ophthalmic Surgery)
RevitalVision’s CEO, Yair Yahav, participated in the 2024 AECOS innovation forum, which featured eight top industry innovations. The forum was moderated by Mr. William Link, PhD.
April 2023
AAPOS 23 annual meeting- presenting poster with mid term study results
During the 48th annual meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS 23), Dr. Sigal Zmujack’s presented the mid-term results of two new controlled randomized studies evaluating RevitalVision’s efficacy in improving vision in nystagmus and amblyopia patients aged 9-55, which both showed significant anti-suppression effects.
Download the poster
January 2023
Narayana Nethralaya Eye Foundation – What & how does my child see Conference
RevitalVision CEO Yair Yahav was a guest speaker at the Narayana Nethralaya Eye Foundation symposium on Amblyopia, Binocular Vision, Cortical Visual Impairment, and Low Vision.
He presented a scientific & clinical review on Optimizing Cortical Visual Functions with RevitalVision.
January 2023
A new published study on RevitalVision treatment
This independent study, which was published in Vision Development and Rehabilitation: COVD’s Digital Journal, evaluated the efficacy of RevitalVision’s perceptual-based vision training program, in improving visual acuity in adult amblyopic individuals beyond occlusion.
Read the full publication (p.260)
November22
Margalit Startup City Haifa- Digital Health Accelerator
We are proud to have been selected as one of the companies to participate in Margalit Startup City’s digital health accelerator in Haifa.
Read more
November22
Ophthalmology Innovation Source Summit (OIS)
Our CEO Yair Yahave presented at the OIS Israel (Ophthalmology Innovation Source Summit) during the MIXiii Health-Tech.IL conference between 9-10 November at the ICC in Jerusalem.
October 2022
Presenting at the ACADEMY 2022 SAN DIEGO
The American Academy of Optometry’s annual meeting
October 2022
RevitalVision at EPOS 2022 Munich
47th Meeting of European Paediatric Ophthalmological Society
September 2022
Israel: A beacon of light helping with sight
This special feature article in GeekTime profiles innovative optics treatments and technologies from leading start-ups.
To the full article
RevitalVision will present at ESCRS2022
We will be presenting at the 40th annual congress of The European Society for Cataract and Refractive Surgery (ESCRS) in Milan, Italy, from 16-19 September 2022.
For more information on the ESCRS congress
May2022
RevitalVision at the AAO 2022 mid year press relase
March 2022
New randomized controlled trial on RevitalVision
Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial
The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.
The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.
Read the full study
March 2022
RevitalVision will present at the AAPOS 2022 – Arizona
2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.
RevitalVision at HIMSS 22
This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companies
November 2021
RevitalVision on The Ophthalmologist
Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia
3-6 November 2021
American Academy of Optometry Annual Meeting
We’re excited to be one of the exhibitors at the American Academy of Optometry Annual Meeting – which will be taking place in Boston. Visit us in the exhibit hall at booth #843
12-15 November 2021
American Academy of Ophthalmology Annual Meeting
Come meet our experts at the AAO annual meeting, taking place in New Orleans this November
July 2021
RevitalVision received reimbursement code in the USA
RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).
02/11/2020
RevitalVision New Product Release
We are happy to announce the release of our new web vision training software application with RevitalVision new branding. This advance software, which is designed to improve vision by improving the brain visual processing, is easier to use and provides better patient feedback.
01/08/2020
WSPOS – World Wide Webinar on Amblyopia – Sponsored by REVITALVISION
World Society of Pediatric Ophthalmology and Strabismus
21-24 April 2021
REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)
Meeting in PARIS 21th /24th April 2021
Link to article
2020
A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)
meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopia
Download ppt
7 October
REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)
Meeting in Nashville, TN, USA 7-10 October
Link to article
2020
Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study
A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)
